drugset / Trial / NCT04572763
Copanlisib Plus Venetoclax in R/R DLBCL
Phase 1/2
Active not recruiting
48 enrolled
Dana-Farber Cancer Institute
AbbVie · collabBayer · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This research study is evaluating the combination of two drugs, copanlisib and venetoclax, as a possible treatment for trelapsed/refractory diffuse large B-cell lymphoma (DLBCL) The names of the study drugs involved in this study are: * Copanlisib * Venetoclax
Timeline
- Start
- 2021-09-08
- Primary completion
- 2025-07-29
- Completion
- 2026-07-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Copanlisib | Small molecule | — | Intravenous |
| Subject | Venetoclax | Small molecule | — | Oral |